A5103217277- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Virus-based gene therapy research
- Immune cells in cancer
- Neuroinflammation and Neurodegeneration Mechanisms
- Parvovirus B19 Infection Studies
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Single-cell and spatial transcriptomics
- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
Luxembourg Institute of Health
2020-2024
University of Luxembourg
2023-2024
Despite decades of research and the best up-to-date treatments, grade 4 Glioblastoma (GBM) remains uniformly fatal with a patient median overall survival less than 2 years. Recent advances in immunotherapy have reignited interest utilizing immunological approaches to fight cancer. However, current immunotherapies so far not met anticipated expectations, achieving modest results their journey from bench bedside for treatment GBM. Understanding intrinsic features GBM is crucial importance...
Numerous patient-based studies have highlighted the protective role of immunoglobulin E-mediated allergic diseases on glioblastoma (GBM) susceptibility and prognosis. However, mechanisms behind this observation remain elusive. Our objective was to establish a preclinical model able recapitulate phenomenon investigate immunity underlying such protection.An immunocompetent mouse airway inflammation (AAI) initiated before intracranial implantation GBM cells (GL261). RAG1-KO mice served assess...
The authors have nothing to disclose. original article with the respective data information can be found at doi: 10.1038/s41590-022-01326-8.
The immunosuppressive nature of the tumor microenvironment poses a significant challenge to effective immunotherapies against glioblastoma (GB). Boosting immune response is critical for successful therapy. Here, we adopted cancer gene therapy approach induce T‐cell‐mediated killing through increased activation system. Patient‐based three‐dimensional (3D) GB models were infected with replication‐deficient adenovirus (AdV) armed class II major histocompatibility complex (MHC‐II) transactivator...
Abstract Background Although immunotherapies represent an encouraging approach against cancer, to date none translated the clinical benefit in Glioblastoma (GBM). One aspect contributing this failure is highly immunosuppressive GBM microenvironment. Our overcome immunosuppression increase anti-tumor immune responses via adenovirus (AdV)-mediated delivery of MHC-II Transactivator (CIITA) gene. CIITA-induced expression anticipated convert cells into surrogate antigen presenting able prime T...